The effect of lanosterol on platelet aggregation in human platelets.
It has been reported that lanosterol can sensitize isolated rat platelets to agonists such as ADP and thrombin (4). The purpose of this paper was to determine whether lanosterol had similar effects on human platelets and whether this was achieved by changes in membrane fluidity. Lanosterol did increase the sensitivity of human platelets, particularly to adrenaline and ADP at concentrations as low as 5 mg.L-1 when added from solutions in ethanol. At similar concentrations cholesterol, 4-cholesten-3-one or ethynyloestradiol had either no effect or were inhibitory. Measurement of membrane fluidity with diphenylhexatriene indicated that lanosterol did not affect membrane fluidity. Incubation of platelets with [4C]-mevalonic acid gave rise to a very small incorporation into lanosterol, squalene and farnesol. Sudden activation of the platelets did not accelerate lanosterol synthesis during or after platelet aggregation. It was concluded that lanosterol could only influence platelet behaviour if it came from the plasma. However the concentration of the steroid in both platelets and plasma is ten fold less than that required to sensitise the platelets.
D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D002784:Cholesterol / Q000097:blood; D006801:Humans; D066298:In Vitro Techniques; D007810:Lanosterol / Q000097:blood / Q000494:pharmacology*; D008560:Membrane Fluidity / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects*; D013256:Steroids / Q000097:blood / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology
D013256:Steroids; D007810:Lanosterol; D002784:Cholesterol; D013917:Thrombin